Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

David Cox

Cardiovascular Disease Charlotte, NC Medical Doctor

NPI 1649278011 CMS profile 346966

10650 Park Rd, Charlotte, NC 28210

Open in the dashboard

General payments

$25,691

121 records reported · program years 2019–2025

Research payments

$108

Paid to them · 1 record reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, David Cox of Charlotte, NC is reported in the CMS Open Payments database as having received $25,691 across 121 general payments and $108 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 90th percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,285 23
2024 General $1,369 20
2024 Research $108 1
2023 General $1,435 13
2022 General $8,984 34
2021 General $1,702 6
2020 General $324 6
2019 General $10,591 19

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • David Cox
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to David Cox were reported at $1,285. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year David Cox Cardiovascular Disease median Middle half National median
2019 $10,591 $450 $127–$1,392 $163
2020 $324 $242 $77–$751 $114
2021 $1,702 $335 $101–$1,037 $132
2022 $8,984 $395 $121–$1,211 $149
2023 $1,435 $443 $136–$1,283 $160
2024 $1,369 $450 $136–$1,323 $164
2025 $1,285 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic, Inc. $10,535 38 payments
  2. Biotronik Inc. $8,800 3 payments
  3. Boston Scientific Corporation $1,237 19 payments
  4. Siemens Medical Solutions USA, Inc. $676 7 payments
  5. Abiomed $649 12 payments
  6. Medtronic Vascular, Inc. $641 2 payments
  7. CeloNova BioSciences, Inc. $531 1 payment
  8. Abbott Laboratories $410 5 payments
  9. Teleflex LLC $384 3 payments
  10. Ostial Corporation $325 1 payment
  11. Other $1,503 30 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program $8,800 3 payments
  2. Food and Beverage $6,667 98 payments
  3. Consulting Fee $5,963 2 payments
  4. Travel and Lodging $2,911 16 payments
  5. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $1,350 1 payment
  6. Education $0 1 payment
Products named General payments · program years 2019–2025
  1. RESOLUTE ONYX $1,730 17 payments
  2. ADVISA DR MRI SURESCAN $1,539 8 payments
  3. Resolute $1,350 1 payment
  4. AVVIGO Guidance System $701 9 payments
  5. Artis icono floor $595 5 payments
  6. CoreValve Evolut $563 1 payment
  7. FLASH Ostial System $325 1 payment
  8. Impella $311 7 payments
  9. GUIDELINER $278 2 payments
  10. TherOx DS2 Console $231 1 payment
  11. Other $3,280 55 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Abiomed $108 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 15 drugs

Part D claims

592

Median for Interventional Cardiology: 2,236

Drug cost

$100,580

Median for Interventional Cardiology: $380,412

Branded share of claims

44.8%

Median for Interventional Cardiology: 27.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 104 $78,828
Entresto Sacubitril/Valsartan Brand 13 $17,199
Clopidogrel Clopidogrel Bisulfate Brand 137 $1,136
Prasugrel Hcl Generic 14 $800
Metoprolol Succinate Generic 55 $574
Amlodipine Besylate Generic 44 $432
Atorvastatin Calcium Generic 51 $391
Carvedilol Generic 33 $355
Isosorbide Mononitrate Er Isosorbide Mononitrate Brand 11 $265
Losartan Potassium Generic 37 $219

The 10 drugs with the highest cost, of 15 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 4,694 Part D prescribers listed as Interventional Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 64 billing codes

Paid by Medicare

$137,039

Medicare's payments for the services billed

Medicare patients

359

Average age 75

Services billed

1,221

149 women, 210 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 75%
Arthritis 47%
Heart failure 43%
Atrial fibrillation 38%
Diabetes 33%
Chronic kidney disease 33%
Depression 22%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

122 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record